Type, Metastasis, Treatment and Liver Cancer Chemotheraphy Drugs..

.

TYPE OF LIVER CANCER.

Primary Liver Cancer 

• Cholangio Carcinoma, cancer that starts in the bile duct.  
• Hepatoblastoma, generally attacking children or child who experienced puberty. 
• Angiosarcoma, a rare cancer, began in the existing blood vessels in the liver. 
• Hepatoma (HCC)-originated in hepatocytes and can spread to other organs. Men are twice as prone to this disease than women.

Secondary Liver Cancer

Secondary liver cancer can arise from primary liver cancer in other organs. But, generally its sourced from the stomach, pancreas, colon, and rectum

M E T A S T A S I S

Normal cells can turn into cancer cells are caused by expression of oncogenes. Oncogene originated from the proto-oncogenes (involved in the activity of normal eukaryotic cell growth) are mutated. If the oncogene is active, then the cells will have uncontrolled growth.

TREATMENTTREATMENT FOR LIVER CANCER

• Surgery.

• Radiation therapy.

• Chemotherapy.

• Kemoembolisasi.

• Gene Therapy.

• Cryotherapy.

• Radiofrequency ablation.

• Transplant.

 Supplementation of vitamin B3 or niacin reported also can prevent cancer. This vitamin is usually also be given in patients with cancer who are undergoing chemotherapy, to reduce the toxic effects (toxicity) of chemotherapy itself.

Alkilgliserol are widely available in fish liver oils shark, co enzyme Q10, butyric acid,, cartilage antiangiogenesis factor (from sharks) that serves prevent the formation of new blood in the spread cancer cells.  Also, omega-3 from fish oil, omega 6 as well as some plant extracts of plants such as bromelain from pineapple trees, onions White (Allium sativum), onions (Allium cepa)) and the substance of lentinan derived from shiitake mushroom from Japan.

             

  LIVER CANCER CHEMOTHERAPY DRUGS.

•  Zadaxin.
•  Doxorubicin.
• Methotrexate.
• 5FU.
• Cisplatin.
• Colchicine, for liver cancer prevention patients with end-stage hepatitis

GANKYRIN AS A TARGET OF ANTI- LIVER CANCER DRUG 

Gankyrin → as a cofactor that enhances the activity of MDM2 and p53.

Gankyrin binds to Rb and the S6 ATPase subunit in the 26s proteosome.

Gankyrin also binds to Cdk4 and prevents the inhibition of tumor supressor.

p53 has anti-proliferative effects, including apoptosis.

Gankyrin decreased p53 → → degraded cells continue to divide uncontrollably

Drug delivery in the body is divided into 4 :

•  Absorption.

•  Distribution.

•  Metabolism.

•  Excretion.

Drug interactions may occur through the process of delivery as a result of endogenous and exogenous factors.